GlassScriptPhysician profile
Kristie Driver
NPI 1003227141
$15,103.94
in general payments reported to CMS, 2019-2025
65 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,461 · 2020: $1,683 · 2021: $2,853 · 2022: $2,246 · 2023: $2,592 · 2024: $2,714 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,861.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,782.66 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,787.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,312.94 | 2019-2025 | Repatha, Aimovig, Otezla |
| Novo Nordisk INC | $1,175.14 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $1,019.58 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $834.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $617.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $397.88 | 2019-2025 | Ajovy, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $317.63 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $280.41 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $277.82 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $251.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.48 | 2019-2025 | Ofev, Jardiance |
| Biohaven Pharmaceuticals, INC. | $214.65 | 2020-2021 | |
| Exact Sciences Corporation | $208.75 | 2023-2025 | Cologuard Collection Kit |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristie Driver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.